Silencing of miR-34a Attenuates Cardiac Dysfunction in a Setting of Moderate, but Not Severe, Hypertrophic Cardiomyopathy
Figure 5
Analysis of miR-34a target gene or protein expression.
(A) Representative Western blots and quantification of VEGF-A and VCL relative to GAPDH in hearts of control (con), TAC moderate (mod), TAC severe (sev) mice dosed with either LNA-control (c) or LNA-antimiR-34a (a). N = 3–5 per group. ∧P<0.05 vs. control when using 1 way ANOVA followed by Fisher’s Post Hoc test on severe group only. (B) qPCR analysis of Sirt1, Sema4b, Vegfb, Pofut1, PNUTS (Pppr10), Notch 1 and Cyclin D1 (Ccnd1) relative to Hprt1. N = 3–5 per group. ∧P<0.05 vs. control when using 1 way ANOVA followed by Fisher’s Post Hoc test on control and TAC severe groups only (comparing three groups).